We are live on ! Find out more
Perceptive Advisors

Perceptive Advisors Portfolio holdings

AUM $5.74B Turnover 38.06%
1-Year Est. Return 183.85%
 

Perceptive Advisors is a life sciences investment firm whose flagship Perceptive Life Sciences Fund puts most of its money into publicly traded small and mid-sized companies. Joseph Edelman, a former senior analyst at Paramount Capital's Aries Fund, a biotechnology hedge fund, founded the firm in 1999. It launched its first credit fund in 2013, and in 2019 teamed up with the biotech startup accelerator Xontogeny to launch its first venture capital fund.

This Fund
S&P 500
This Quarter Est. Return
+59.82%
1 Year Est. Return
+183.85%
3 Year Est. Return
+1,392.3%
5 Year Est. Return
+3,239.37%
10 Year Est. Return
+33,396.11%
AUM
$1.55B
AUM Growth
+$107M
Cap. Flow
-$72.8M
Cap. Flow %
-4.7%
Top 10 Hldgs %
49.99%
Holding
236
New
61
Increased
26
Reduced
57
Closed
43
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
1.4 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
1.4 years
Top 20 Avg Time Held Equity only
1.3 years

Sector Composition

Rank Sector Weight
1 Healthcare 96.62%
2 Miscellaneous 2.58%
3 Consumer Staples 0.5%
4 Technology 0.1%
5 Consumer Discretionary 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
SRPT icon
1
Sarepta Therapeutics
SRPT
$1.43B
$209M 13.46%
3,395,236
-372,080
-10% -$11.2M
2013 Q2
13 quarters
NBIX icon
2
Neurocrine Biosciences
NBIX
$15.2B
$125M 8.09%
2,476,272
-321,695
-11% -$16M
2013 Q2
13 quarters
FOLD icon
3
DELISTED
Amicus Therapeutics
FOLD
$104M 6.74%
14,116,644
-1,122,800
-7% -$7.58M
2014 Q1
10 quarters
TSRO
4
DELISTED
Tesaro
TSRO
$68.4M 4.42%
682,415
-461,200
-40% -$43.1M
2013 Q2
13 quarters
TVTX icon
5
Travere Therapeutics
TVTX
$4.51B
$54.8M 3.53%
2,446,482
-832,898
-25% -$15.9M
2014 Q1
10 quarters
GBT
6
DELISTED
Global Blood Therapeutics
GBT
$53.8M 3.47%
2,334,168
+126,500
+6% +$2.41M
2015 Q3
4 quarters
ARAV
7
DELISTED
Aravive
ARAV
$49.4M 3.19%
671,448
+198,822
+42% +$14.4M
2014 Q1
10 quarters
NXTM
8
DELISTED
NxStage Medical
NXTM
$41.7M 2.69%
1,669,703
+287,293
+21% +$6.7M
2016 Q2
1 quarter
XNCR icon
9
Xencor
XNCR
$2.5B
$36.6M 2.37%
1,496,229
-33,345
-2% -$705K
2013 Q4
11 quarters
LJPC
10
DELISTED
La Jolla Pharmaceutical
LJPC
$31.5M 2.03%
1,323,324
-9,491
-0.7% -$179K
2014 Q3
8 quarters
IOVA icon
11
Iovance Biotherapeutics
IOVA
$3.19B
$29.4M 1.9%
3,567,553
-44,423
-1% -$376K
2015 Q1
6 quarters
WVE icon
12
Wave Life Sciences
WVE
$505M
$22.2M 1.43%
683,448
+160,853
+31% +$3.8M
2016 Q1
2 quarters
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$21.3M 1.38%
589,890
-13,146
-2% -$435K
2014 Q2
9 quarters
CLCD
14
DELISTED
CoLucid Pharmaceuticals
CLCD
$21.1M 1.36%
+552,030
New +$8.16M
2016 Q3
0 quarters
TLPH icon
15
Talphera
TLPH
$40.8M
$21M 1.36%
270,436
-29,352
-10% -$1.95M
2013 Q2
13 quarters
QTNT
16
DELISTED
Quotient Ltd
QTNT
$20.9M 1.35%
66,795
+10,568
+19% +$2.97M
2014 Q2
9 quarters
DBVT icon
17
DBV Technologies
DBVT
$567M
$20.5M 1.32%
56,327
+1,657
+3% +$576K
2015 Q2
5 quarters
CRBP icon
18
Corbus Pharmaceuticals
CRBP
$42.4M
$18.3M 1.18%
90,034
-16,633
-16% -$2.07M
2015 Q2
5 quarters
RGNX icon
19
Regenxbio
RGNX
$473M
$18M 1.16%
1,282,286
+183,073
+17% +$2.02M
2015 Q3
4 quarters
RDUS icon
20
DELISTED
Radius Health
RDUS
$17M 1.09%
+313,502
New +$15.9M
2016 Q3
0 quarters
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$16.9M 1.09%
+1,363,711
New +$17.8M
2016 Q3
0 quarters
KDMN
22
DELISTED
Kadmon Holdings
KDMN
$16.2M 1.05%
+2,209,657
New +$20.1M
2016 Q3
0 quarters
DXCM icon
23
DexCom
DXCM
$29.6B
$15.7M 1.01%
715,396
+214,700
+43% +$4.78M
2016 Q1
2 quarters
AERI
24
DELISTED
Aerie Pharmaceuticals
AERI
$15.4M 0.99%
+406,771
New +$8.97M
2016 Q3
0 quarters
ALDX icon
25
Aldeyra Therapeutics
ALDX
$50.7M
$15.2M 0.98%
1,940,458
– –
2015 Q1
6 quarters

Similar funds

Perceptive Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Perceptive Advisors held 236 positions worth $1.55B, up 7.4% from $1.44B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors withdrew a net $72.8M in Q3 2016, closing 43 positions and reducing 57 holdings. Its most notable exit was Medivation, an estimated $45.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 79% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Kadmon Holdings worth $16.2M.

  • Perceptive Advisors's largest Q3 2016 buy was Kadmon Holdings: 2,209,657 shares worth $16.2M.
  • Perceptive Advisors added most to Aravive in Q3 2016, an estimated $14.4M increase.
  • Perceptive Advisors's biggest Q3 2016 reduction was Tesaro, cutting an estimated $43.1M.
  • Perceptive Advisors fully exited Medivation in Q3 2016, selling an estimated $45.8M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.55B portfolio in Q3 2016.
  • Perceptive Advisors opened 61 new positions and closed 43 in Q3 2016.
  • Perceptive Advisors's portfolio value rose 7.4% quarter-over-quarter to $1.55B.

Based on Perceptive Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.